Table 3.
Comparison of clinico-pathologic features between 374 patients of ASCO/CAP group 5 and 57 primary breast cancer patients of ASCO/CAP group 2 who underwent modified radical mastectomy without neoadjuvant therapy
| Characteristics | Group 2 | Group 5 | p |
|---|---|---|---|
| HER2/CEP17 ≥ 2; HER2 copy<4 n = 57(%) | HER2/CEP17 < 2; HER2 copy<4 n = 374(%) | ||
| Age (year) | 0.73 | ||
| ≤ 50 | 27 (47.4) | 168 (44.9) | |
| > 50 | 30 (52.6) | 206 (55.1) | |
| Histologic grade | 0.03 | ||
| G1 | 0 | 6 (1.6) | |
| G2 | 22 (38.6) | 208 (55.6) | 0.03 |
| G3 | 35 (61.4) | 160 (42.8) | |
| Pathologic stage | 0.79 | ||
| T1 | 20 (39.2) | 131 (35.0) | |
| T2 | 28 (54.9) | 224 (59.9%) | |
| T3 | 3 (5.9) | 19 (5.1) | |
| Lymph node status | 0.02 | ||
| pN0 | 20 (35.1) | 150 (40.1) | |
| pN1 | 20 (35.1) | 136 (36.4) | |
| pN2 | 13 (22.8) | 84 (22.5) | |
| pN3 | 4 (7.0) | 4 (1.1) | |
| AJCC staging | 0.84 | ||
| I | 9 (17.6) | 64 (17.1) | |
| II | 27 (52.9) | 213 (57.0) | |
| III | 15 (29.4) | 97 (25.9) | |
| ER | 0.04 | ||
| Positive | 44 (77.2) | 326 (87.2) | |
| Negative | 13 (22.8) | 48 (12.8) | |
| PR | 0.16 | ||
| Positive | 38 (66.7) | 282 (75.4) | |
| Negative | 19 (33.3) | 92 (24.6) | |
| Ki67 | 0.03 | ||
| ≥ 30% | 26 (45.6) | 115 (30.7) | |
| < 30% | 31 (54.4) | 259 (69.3) | |
| Immunohistochemical surrogate subtype | 0.12 | ||
| Lumina A-Like | 18 (31.6) | 107 (28.6) | |
| Lumina B-Like | 27 (47.4) | 221 (59.1) | |
| TNBC | 12 (21.1) | 46 (12.3) |